Subcutaneous blinatumomab plus TKI drives high remission in relapsed Ph+ acute lymphoblastic leukaemia

Prof Elias Jabbour speaks to ecancer about a phase 1/2 study that evaluated a subcutaneous formulation of blinatumomab in adults with heavily pretreated relapsed or refractory Philadelphia chromosome–positive B-cell acute lymphoblastic leukaemia, including patients previously treated with multiple therapies such as TKIs, CAR-T, and prior blinatumomab.

Subcutaneous blinatumomab demonstrated high efficacy, with over 80% of patients achieving complete remission or partial haematologic recovery within two cycles, and most responders achieving deep molecular responses with MRD negativity.

The treatment was effective even when combined with concurrent tyrosine kinase inhibitors, with no new safety concerns identified.

A subset of patients successfully proceeded to stem cell transplant or CAR-T therapy, highlighting its role as a bridging strategy.

Prof Jabbour highlights that these results support subcutaneous blinatumomab as a promising, more convenient alternative to continuous infusion, delivering strong remission rates and deep responses in patients with relapsed Ph+ ALL.